Ruxer Jan, Mozdzan Michał, Loba Jerzy, Markuszewski Leszek
Kliniki Kardiologii Interwencyjnej, Kardiodiabetologii i Rehabilitacji Kardiologicznej, Uniwersytetu Medycznego w Lodzi.
Wiad Lek. 2007;60(5-6):235-40.
The aim of this study was to comprise the efficacy of chronic therapy with fosfomycin, co-trimoxazole and nitrofurantoin in the treatment and prevention of recurrent urinary tract infections (UTI) in type 2 diabetic women.
The study comprised 90 women aged 50-70 years, who suffered from the UTI (isolated bacterial uropathogen sensitive to fosfomycin, co-trimoxazole and nitrofurantoin). Women were divided into 3 groups. Group I comprised patients, who have been treated with fosfomycin, group II with co-tromixazole and group III with nitrofurantoin. Observation period lasted 9 months and for the 6 months patients were treated with antimicrobial agents. Efficacy of antimicrobial treatment was estimated when both clinical cure and bacteriological eradication of uropathogens were achieved.
There were no significant differences in the percentage of patients between study groups, who achieved therapeutic successes after 3 and 6 months of the antimicrobial treatment (NS). Three months after discontinuation of treatment episodes of UTI were observed significantly rarely in group treated with fosfomycin in comparison with the group treated with nitrofurantoin (p = 0.01) and co-trimoxazole (p = 0.02).
Fosfomycin, co-trimoxazole and nitrofurantoin are safe and effective antimicrobial methods to cure and prevent UTI. Fosfomycin is associated with rarely recurrence of UTI than nitrofurantoin and co-trimoxazole in the period without its taking.
本研究的目的是比较磷霉素、复方新诺明和呋喃妥因长期治疗及预防2型糖尿病女性复发性尿路感染(UTI)的疗效。
本研究纳入了90名年龄在50 - 70岁之间、患有UTI(分离出的尿路致病菌对磷霉素、复方新诺明和呋喃妥因敏感)的女性。将女性分为3组。第一组为接受磷霉素治疗的患者,第二组为接受复方新诺明治疗的患者,第三组为接受呋喃妥因治疗的患者。观察期持续9个月,其中6个月患者接受抗菌药物治疗。当实现临床治愈且尿路致病菌细菌学根除时评估抗菌治疗的疗效。
在抗菌治疗3个月和6个月后取得治疗成功的研究组患者百分比之间无显著差异(无统计学意义)。与接受呋喃妥因治疗的组(p = 0.01)和复方新诺明治疗的组(p = 0.02)相比,停用治疗3个月后,接受磷霉素治疗的组UTI发作明显较少。
磷霉素、复方新诺明和呋喃妥因是治疗和预防UTI的安全有效的抗菌方法。在未服用磷霉素期间,与呋喃妥因和复方新诺明相比,磷霉素与UTI复发较少相关。